ImmuCell (NASDAQ:ICCC) Stock Price Passes Above 200-Day Moving Average – Here’s Why

ImmuCell Corporation (NASDAQ:ICCC) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $6.12 and traded as high as $6.72. ImmuCell shares last traded at $6.56, with a volume of 10,233 shares.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of ImmuCell in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

ImmuCell Price Performance

The firm has a 50 day moving average price of $5.78 and a 200 day moving average price of $6.12. The stock has a market capitalization of $59.37 million, a PE ratio of 25.23 and a beta of 0.18. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The company had revenue of $5.51 million for the quarter. ImmuCell had a net margin of 8.37% and a return on equity of 8.00%.

Institutional Investors Weigh In On ImmuCell

A hedge fund recently raised its stake in ImmuCell stock. Steadtrust LLC raised its position in shares of ImmuCell Corporation (NASDAQ:ICCC) by 79.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 56,770 shares of the biotechnology company’s stock after purchasing an additional 25,070 shares during the quarter. Steadtrust LLC owned 0.63% of ImmuCell worth $349,000 as of its most recent SEC filing. Institutional investors and hedge funds own 13.47% of the company’s stock.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.